Literature DB >> 26468204

Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease.

Antonella Caccamo1, Caterina Branca2, Joshua S Talboom3, Darren M Shaw3, Dharshaun Turner4, Luyao Ma4, Angela Messina5, Zebing Huang4, Jie Wu6, Salvatore Oddo7.   

Abstract

Aging is the most important risk factor associated with Alzheimer's disease (AD); however, the molecular mechanisms linking aging to AD remain unclear. Suppression of the ribosomal protein S6 kinase 1 (S6K1) increases healthspan and lifespan in several organisms, from nematodes to mammals. Here we show that S6K1 expression is upregulated in the brains of AD patients. Using a mouse model of AD, we found that genetic reduction of S6K1 improved synaptic plasticity and spatial memory deficits, and reduced the accumulation of amyloid-β and tau, the two neuropathological hallmarks of AD. Mechanistically, these changes were linked to reduced translation of tau and the β-site amyloid precursor protein cleaving enzyme 1, a key enzyme in the generation of amyloid-β. Our results implicate S6K1 dysregulation as a previously unidentified molecular mechanism underlying synaptic and memory deficits in AD. These findings further suggest that therapeutic manipulation of S6K1 could be a valid approach to mitigate AD pathology. SIGNIFICANCE STATEMENT: Aging is the most important risk factor for Alzheimer's disease (AD). However, little is known about how it contributes to AD pathogenesis. S6 kinase 1 (S6K1) is a protein kinase involved in regulation of protein translation. Reducing S6K1 activity increases lifespan and healthspan. We report the novel finding that reducing S6K1 activity in 3xTg-AD mice ameliorates synaptic and cognitive deficits. These improvement were associated with a reduction in amyloid-β and tau pathology. Mechanistically, lowering S6K1 levels reduced translation of β-site amyloid precursor protein cleaving enzyme 1 and tau, two key proteins involved in AD pathogenesis. These data suggest that S6K1 may represent a molecular link between aging and AD. Given that aging is the most important risk factor for most neurodegenerative diseases, our results may have far-reaching implications into other diseases.
Copyright © 2015 the authors 0270-6474/15/3514042-15$15.00/0.

Entities:  

Keywords:  AD; Aβ; aging; mTOR; plaques; tangles

Mesh:

Substances:

Year:  2015        PMID: 26468204      PMCID: PMC4604237          DOI: 10.1523/JNEUROSCI.2781-15.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  47 in total

1.  An examination of psychometric properties of the mini-mental state examination and the standardized mini-mental state examination: implications for clinical practice.

Authors:  V C Pangman; J Sloan; L Guse
Journal:  Appl Nurs Res       Date:  2000-11       Impact factor: 2.257

2.  Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

Authors:  Salvatore Oddo; Antonella Caccamo; Jason D Shepherd; M Paul Murphy; Todd E Golde; Rakez Kayed; Raju Metherate; Mark P Mattson; Yama Akbari; Frank M LaFerla
Journal:  Neuron       Date:  2003-07-31       Impact factor: 17.173

Review 3.  Methods for monitoring autophagy.

Authors:  Noboru Mizushima
Journal:  Int J Biochem Cell Biol       Date:  2004-12       Impact factor: 5.085

Review 4.  Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Biochem Pharmacol       Date:  2014-01-04       Impact factor: 5.858

5.  Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology.

Authors:  Miranda E Orr; Angelica Salinas; Rochelle Buffenstein; Salvatore Oddo
Journal:  Neurobiol Aging       Date:  2013-12-14       Impact factor: 4.673

Review 6.  Selective manipulation of aging: a novel strategy for the treatment of neurodegenerative disorders.

Authors:  Lorna Moll; Tayir El-Ami; Ehud Cohen
Journal:  Swiss Med Wkly       Date:  2014-02-13       Impact factor: 2.193

7.  2014 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2014-03       Impact factor: 21.566

8.  Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway.

Authors:  Pankaj Kapahi; Brian M Zid; Tony Harper; Daniel Koslover; Viveca Sapin; Seymour Benzer
Journal:  Curr Biol       Date:  2004-05-25       Impact factor: 10.834

9.  Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity.

Authors:  Sung Hee Um; Francesca Frigerio; Mitsuhiro Watanabe; Frédéric Picard; Manel Joaquin; Melanie Sticker; Stefano Fumagalli; Peter R Allegrini; Sara C Kozma; Johan Auwerx; George Thomas
Journal:  Nature       Date:  2004-08-11       Impact factor: 49.962

10.  Alzheimer's disease brain: alterations in RNA levels and in a ribonuclease-inhibitor complex.

Authors:  E M Sajdel-Sulkowska; C A Marotta
Journal:  Science       Date:  1984-08-31       Impact factor: 47.728

View more
  41 in total

1.  Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer's disease.

Authors:  Caterina Branca; Eric Ferreira; Thuy-Vi Nguyen; Kristian Doyle; Antonella Caccamo; Salvatore Oddo
Journal:  Hum Mol Genet       Date:  2017-12-15       Impact factor: 6.150

2.  PRAS40 alleviates neurotoxic prion peptide-induced apoptosis via mTOR-AKT signaling.

Authors:  Wei Yang; Li-Feng Yang; Zhi-Qi Song; Syed Zahid Ali Shah; Yong-Yong Cui; Chao-Si Li; Hua-Fen Zhao; Hong-Li Gao; Xiang-Mei Zhou; De-Ming Zhao
Journal:  CNS Neurosci Ther       Date:  2017-03-14       Impact factor: 5.243

3.  Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease.

Authors:  Ramon Velazquez; An Tran; Egide Ishimwe; Larry Denner; Nikhil Dave; Salvatore Oddo; Kelly T Dineley
Journal:  Neurobiol Aging       Date:  2017-06-17       Impact factor: 4.673

4.  The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway.

Authors:  Lin Li
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

5.  Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation.

Authors:  Chuanzhou Li; Jürgen Götz
Journal:  EMBO J       Date:  2017-09-01       Impact factor: 11.598

6.  Genetically reducing mTOR signaling rescues central insulin dysregulation in a mouse model of Alzheimer's disease.

Authors:  Antonella Caccamo; Ramona Belfiore; Salvatore Oddo
Journal:  Neurobiol Aging       Date:  2018-04-05       Impact factor: 4.673

7.  Forebrain depletion of Rheb GTPase elicits spatial memory deficits in mice.

Authors:  Neelam Shahani; Wen-Chin Huang; Megan Varnum; Damon T Page; Srinivasa Subramaniam
Journal:  Neurobiol Aging       Date:  2016-11-21       Impact factor: 4.673

Review 8.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 9.  The mTOR signalling cascade: paving new roads to cure neurological disease.

Authors:  Peter B Crino
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

Review 10.  Metabolic aspects of neuronal degeneration: From a NAD+ point of view.

Authors:  Yo Sasaki
Journal:  Neurosci Res       Date:  2018-07-10       Impact factor: 3.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.